The company claims that Cobroxin is the first over-the-counter (OTC) pain reliever, clinically proven to treat moderate-to-severe (stage 2) chronic pain. Many other stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin.
The drug is currently available as an oral spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia. It is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
The company said that to support sales of Cobroxin, it has committed to a $4m print advertising campaign for the first 12-months. The campaign includes advertisements in Health, Prevention, Self, Soap Opera Digest, Working Mother, Woman’s Day, Shape, Martha Stewart, Redbook, Ladies Home Journal, Allure, Wired, Web MD and Arthritis Today magazines.
Frank Rizzo, president and CEO of XenaCare, said: “Sales of Cobroxin have already exceeded our projections for the beginning of this year. Reorder rates from our customers have been very strong at all levels of our distribution grid and have required us to reorder inventory four times from Nutra Pharma since placing our initial order for the product.”